DDInter1442 DDInter1652
A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Phenobarbital {u} (Compound) resembles {v} (Compound) Primidone
Phenobarbital {u} (Compound) resembles {v} (Compound) Methsuximide
Phenobarbital {u} (Compound) treats {v} (Disease) epilepsy syndrome
Phenobarbital {u} (Compound) binds {v} (Gene) ABCC3
Phenobarbital {u} (Compound) causes {v} (Side Effect) Mental disability
Phenobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomustine
Phenobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Letrozole
Phenobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Promethazine
Phenobarbital {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Phenobarbital {u} may lead to a major life threatening interaction when taken with {v} Sunitinib
Phenobarbital (Compound) resembles Primidone (Compound)
Phenobarbital (Compound) resembles Methsuximide (Compound)
Phenobarbital (Compound) treats epilepsy syndrome (Disease)
Phenobarbital (Compound) binds ABCC3 (Gene)
Phenobarbital (Compound) causes Mental disability (Side Effect)
Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Lomustine
Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Letrozole
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Phenobarbital may lead to a major life threatening interaction when taken with Sunitinib